Aggelos Stefos
Overview
Explore the profile of Aggelos Stefos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koutalos A, Koskiniotis A, Rountas C, Konstantinou E, Georgiadou S, Stefos A, et al.
Eur J Intern Med
. 2024 Jan;
123:127-131.
PMID: 38281818
Background & Aims: During the pandemic, steroids use at various dosages and durations for the treatment of COVID-19 patients, especially in hospitalized patients, was a common and effective strategy. However,...
2.
Gatselis N, Lyberopoulou A, Lygoura V, Giannoulis G, Samakidou A, Vaiou A, et al.
Eur J Intern Med
. 2023 Nov;
122:78-85.
PMID: 37953124
Background & Aims: Calprotectin reflects neutrophil activation and is increased in various inflammatory conditions including severe COVID-19. However, serial serum calprotectin measurements in COVID-19 patients are limited. We assessed prospectively,...
3.
Gatselis N, Lygoura V, Lyberopoulou A, Giannoulis G, Samakidou A, Vaiou A, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458517
Risk stratification of coronavirus disease-19 (COVID-19) patients by simple markers is critical to guide treatment. We studied the predictive value of soluble interleukin-2 receptor (sIL-2R) for the early identification of...
4.
Tsilipounidaki K, Athanasakopoulou Z, Muller E, Burgold-Voigt S, Florou Z, Braun S, et al.
Microorganisms
. 2022 Jan;
10(1).
PMID: 35056608
Carbapenem-resistant Gram-negative bacteria are a public health threat that requires urgent action. The fact that these pathogens commonly also harbor resistance mechanisms for several other antimicrobial classes further reduces patient...
5.
Speletas M, Dadouli K, Syrakouli A, Gatselis N, Germanidis G, Mouchtouri V, et al.
Immunobiology
. 2021 Oct;
226(6):152136.
PMID: 34628288
The COVID-19 pandemic represents one of the greatest challenges in modern medicine. The disease is characterized by a variable clinical phenotype, ranging from asymptomatic carriage to severe and/or critical disease,...
6.
Dalekos G, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G, et al.
Eur J Intern Med
. 2021 Apr;
88:52-62.
PMID: 33820686
Aims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to the development of severe respiratory failure. In hospitalized-patients, prompt interruption of the virus-driven inflammatory process by using combination...
7.
Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos G, Poulakou G, Gatselis N, et al.
Elife
. 2021 Mar;
10.
PMID: 33682678
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml were assigned to...
8.
Akinosoglou K, Kapsokosta G, Mouktaroudi M, Rovina N, Kaldis V, Stefos A, et al.
J Diabetes Complications
. 2020 Nov;
35(1):107765.
PMID: 33187869
Aims: We sought to determine whether primary outcomes differ between non-ICU septic patients with and without type 2 diabetes (T2D). Methods: This study utilized the Hellenic Sepsis Study Group Registry,...
9.
Georgiadou S, Gatselis N, Stefos A, Zachou K, Makaritsis K, Rigopoulou E, et al.
World J Clin Cases
. 2019 Nov;
7(21):3394-3406.
PMID: 31750324
Background: Secondary haemophagocytic lymphohistiocytosis (sHLH) is a rare life-threatening condition mainly associated with underlying infections, malignancies, and autoimmune or immune-mediated diseases. Aim: To analyse all sHLH cases that were diagnosed...
10.
Kyriazopoulou E, Sinapidis D, Halvatzis S, Velissaris D, Alexiou N, Kosmas V, et al.
Int J Antimicrob Agents
. 2019 Nov;
55(1):105836.
PMID: 31704213
Although analysis of retrospective studies has documented survival benefit from the addition of a macrolide to the treatment regimen for community-acquired pneumonia (CAP), no data are available to determine if...